journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Pharmacoeconomics & Outcomes Research

journal
https://www.readbyqxmd.com/read/29764243/the-cost-of-preterm-labor-and-preterm-birth-for-mothers-with-uncomplicated-pregnancies-and-their-infants-in-italy-a-retrospective-cohort-study
#1
Evie Merinopoulou, Shibani Pokras, Jeanne M Pimenta, Valerio Blini, Chiara Veronesi, Stefano Buda, Luca Degli Esposti, Dimitra Lambrelli
BACKGROUND: Preterm labor (PTL)/preterm birth (PTB) impose significant burden on healthcare systems. Women with uncomplicated pregnancies at risk of PTL/PTB have not been widely investigated, and published evidence on the costs of these women and their infants in Italy is absent. We aimed to describe women with uncomplicated pregnancies and associated costs for these women and their infants. METHODS: Data on women aged 12-44 years with uncomplicated pregnancies who delivered between 1/9/2009-31/12/2014 with PTL diagnosis alone or PTL and PTB, were included from four Italian databases...
May 15, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29757040/cost-savings-for-biosimilars-in-the-united-states-a-theoretical-framework-and-budget-impact-case-study-application-using-filgrastim
#2
Simrun Grewal, Scott Ramsey, Sanjeev Balu, Josh J Carlson
OBJECTIVE: Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U.S. METHODS: We developed a framework to illustrate how key factors including regulatory policies, provider and patient perception, pricing, and payer policies impact biosimilar cost-savings...
May 14, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29745736/clinical-outcome-and-prognostic-analysis-of-meningeal-carcinomatosis-treated-by-intrathecal-chemotherapy
#3
Zhaohua Meng, Qinqin Zhang, Kun Hong, Weixin Han, Zeyan Zhao, Yajuan Liu, Junying He, Hui Bu
OBJECTIVE: To evaluate the clinical efficacy of meningeal carcinomatosis (MC) treated by intrathecal chemotherapy (IC) and analyzes the prognostic factors. METHODS: The clinical and follow-up data of 33 MC patients was collected and retrospectively analyzed. Potential prognostic factors such as age, gender, primary cancer, transfer time, presence of brain metastasis, intracranial pressure, protein, glucose, vascular endothelial growth factor (VEGF), eastern cooperative oncology group (ECOG) performance status (PS), systemic treatment and IC were discussed...
May 10, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29741099/economic-evaluation-of-prescribing-conventional-and-newer-oral-anticoagulants-in-older-adults
#4
Syed Shahzad Hasan, Chia Siang Kow, Louise E Curley, Darrin L Baines, Zaheer-Ud-Din Babar
Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted...
May 9, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29733227/health-technology-assessment-in-saudi-arabia
#5
Sinaa Al-Aqeel
The Saudi government, similar to any other government, is committed to making public spending more efficient, using resources more effectively, and limiting waste. Health technology assessment (HTA) is a tool that informs policy and decision makers regarding the formulation of safe and effective policies that are patient-focused and help to achieve efficiency when allocating limited healthcare resources. Areas covered: After a brief description of HTA in the international context, this review provides a brief introduction to Saudi Arabia's healthcare system, followed by a delineation of the decision maker(s) and influencers and the decision-making process for pricing and reimbursement...
May 7, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29707985/how-can-multi-criteria-decision-analysis-support-value-assessment-of-pharmaceuticals-findings-from-a-systematic-literature-review
#6
Katarzyna Kolasa, Vladimir Zah, Marta Kowalczyk
As budget constraints become more and more visible, there is growing recognition for greater transparency and greater stakeholders' engagement in the pharmaceuticals' pric-ing&reimbursement (P&R) decision making. New frameworks of drugs' value assessments are searched for. Among them, the multi-criteria decision analysis (MCDA) receives more and more attention. In 2014, ISPOR established Task Force to provide methodological recommendations for MCDA utilization in the health care decision making. Still, there is not so much knowledge about the real life experience with MCDA's adaptation to the P&R processes...
April 29, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29681201/cost-effectiveness-vs-affordability-in-the-age-of-immuno-oncology-cancer-drugs
#7
George Dranitsaris, Xiaofu Zhu, Georges Adunlin, Mark D Vincent
After years of setback, cancer immunotherapy has begun to yield clinical dividends, which are changing the treatment landscape and offering cancer patients the potential for long-term survival, reduced treatment-related toxicity and improved quality-of-life. Using the immune system to treat cancer is known as 'Immuno-oncology' (IO) and agents are sub-classified by their ability to enhance anti-tumor response or to direct the immune system to attack cancer cells via tumor-associated antigens. Areas covered: Clinical trials have demonstrated the effectiveness of several IO agents in many disease sites such as early and advanced stage melanoma, advanced non-small cell lung cancer, bladder, head and neck, gastric, kidney as well as Hodgkin's lymphoma...
April 25, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29683365/rare-diseases-in-romania-a-response-to-transposition-and-implementation-of-eu-rare-diseases-policy-in-eastern-europe
#8
Emilia Severin
No abstract text is available yet for this article.
April 23, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29676589/association-of-diabetes-diagnosis-with-dietary-changes-and-weight-reduction
#9
Daeho Kim, Kanghyock Koh, Shailender Swaminathan, Amal N Trivedi
BACKGROUND: Lifestyle modifications are associated with better outcomes for patients with diabetes. Patients' awareness of having diabetes may promote lifestyle changes, but there is limited evidence to support this assertion. This study examined whether a report of physician-diagnosed diabetes is associated with dietary changes and efforts to lose weight. METHODS: Cross-sectional comparison of individuals with and without diabetes or prediabetes diagnosis, matched on glycosylated hemoglobin (HbA1c) level, socio-demographic characteristics, and health status using propensity-score matching analysis...
April 20, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29641931/an-italian-cost-effectiveness-analysis-of-paclitaxel-albumin-nab-paclitaxel-gemcitabine-vs-gemcitabine-alone-for-metastatic-pancreatic-cancer-patients-the-apice-study
#10
Carlo Lazzaro, Carlo Barone, Francesco Caprioni, Stefano Cascinu, Alfredo Falcone, Evaristo Maiello, Michele Milella, Carmine Pinto, Michele Reni, Giampaolo Tortora
BACKGROUND: The APICE study evaluates the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel - Nab-P) + gemcitabine (G) vs G alone in metastatic pancreatic cancer (MPC) from the Italian National Health Service (INHS) standpoint. RESEARCH DESIGN AND METHODS: A 4-year, 4 health states (progression-free; progressed; end of life; death) Markov model based on the MPACT trial was developed to estimate costs (Euro [€], 2017 values), and quality-adjusted life years (QALYs)...
April 11, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29448845/a-systematic-review-of-economic-evaluations-of-tyrosine-kinase-inhibitors-of-vascular-endothelial-growth-factor-receptors-mammalian-target-of-rapamycin-inhibitors-and-programmed-death-1-inhibitors-in-metastatic-renal-cell-cancer
#11
Panagiotis Petrou
The therapeutic categories of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors have transformed the treatment of metastatic renal cell cancer. Nevertheless, this comes at an increased cost, in tandem with similar fiscal pressures in the broader oncology sector, which may jeopardize the sustainability of health systems. Areas covered: To this direction, the economic evaluation of these agents is essential for rational and efficient decision-making and resource allocation process...
March 13, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29521147/optimizing-skin-and-skin-structure-infection-outcomes-considerations-of-cost-of-care
#12
S S Almarzoky Abuhussain, K J Goodlet, M D Nailor, D P Nicolau
Skin and skin structure infections (SSSIs) refer to a collection of clinical infectious syndromes involving layers of skin and associated soft tissues. Although associated with less morbidity and mortality than other common skin infections, SSSIs represent a significant increasing source of healthcare expense, with a prevalence of 500 episodes per 10,000 patient-years in the United States resulting in burdening health care systems, of approximately $6 billion annually. Areas covered: Opportunities to reduce costs of care associated with SSSI are highlighted, including transitions of care and avoiding unnecessary hospital admissions...
March 9, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29468951/cost-effectiveness-thresholds-methods-for-setting-and-examples-from-around-the-world
#13
André Soares Santos, Augusto Afonso Guerra-Junior, Brian Godman, Alec Morton, Cristina Mariano Ruas
Cost-effectiveness thresholds (CETs) are used to judge if an intervention represents sufficient value for money to merit adoption in healthcare systems. The study was motivated by the Brazilian context of HTA, where meetings are being conducted to decide on the definition of a threshold. Areas covered: An electronic search was conducted on Medline (via PubMed), Lilacs (via BVS) and ScienceDirect followed by a complementary search of references of included studies, Google Scholar and conference abstracts. Cost-effectiveness thresholds are usually calculated through three different approaches: the willingness-to-pay, representative of welfare economics; the precedent method, based on the value of an already funded technology; and the opportunity cost method, which links the threshold to the volume of health displaced...
February 27, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29466887/access-to-anti-cancer-drugs-in-india-is-there-a-need-to-revise-reimbursement-policies
#14
Gertruud Haitsma, Himanshu Patel, Parthasarathi Gurumurthy, Maarten J Postma
BACKGROUND: The aim of this study was to examine the access of Indian cancer patients to optimum cancer care under selected government schemes by reviewing reimbursement schemes for cancer care in India. METHODS: All cancer care reimbursement schemes in India were identified and three highly utilized schemes (VAS, RAS, CMCHS) were selected. Quality of breast, colorectal, lung, head & neck, and gastric cancer care was reviewed with respect to NCCN guidelines...
February 26, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29486601/balancing-patient-value-and-payer-cost-in-hematologic-malignancies-can-it-be-done
#15
EDITORIAL
Pamela B Allen, Christopher R Flowers
No abstract text is available yet for this article.
April 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29400089/what-are-the-images-used-to-diagnose-and-assess-suspected-strokes-a-systematic-literature-review-of-care-in-four-european-countries
#16
REVIEW
Anne-Claire Peultier, Ken Redekop, Emmanuel Coche, Johan L Severens
The cost-effectiveness of clinical interventions is often assessed using current care as comparator. However, evidence suggests practice variation in stroke imaging across countries. For the purpose of feeding into cost-effectiveness analysis, this research aims to describe the patterns of stroke imaging, examine practice variations across countries and, as such, obtain results reflecting current care. Areas covered: A systematic literature review was conducted to identify original studies reporting the imaging workup used in acute stroke care in clinical practice in Hungary, Germany, Sweden and the UK...
April 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29243501/critical-analysis-of-valuation-and-strategical-orientation-of-merger-and-acquisition-deals-in-the-pharmaceutical-industry
#17
REVIEW
Raphaela Marie Louisa Dierks, Olivier Bruyère, Jean-Yves Reginster
The pharmaceutical industry is undergoing major shifts due to changing macro and micro factors. As the industry is highly capital intensive and patents are expiring, the outlook is on generating inorganic growth, mainly through M&A. Using the income valuation approach, one analyses two completed deals in 2016 above 1bn USD. Thereafter one outlines the main motives behind M&A deals and concluded by discussing whether M&A harms medical innovations. Areas covered: The paper is based on empirical study questioning existing literature in order to critically analyse valuation and the strategical orientation of pharmaceutical companies Expert commentary: Pharmaceutical companies understand the changing market conditions and favour their expertise...
April 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29235882/early-warning-systems-for-the-management-of-chronic-heart-failure-a-systematic-literature-review-of-cost-effectiveness-models
#18
Fernando Albuquerque De Almeida, Maiwenn Al, Ron Koymans, Kadir Caliskan, Ankie Kerstens, Johan L Severens
Describing the general and methodological characteristics of decision-analytical models used in the economic evaluation of early warning systems for the management of chronic heart failure patients and performing a quality assessment of their methodological characteristics is expected to provide concise and useful insight to inform the future development of decision-analytical models in the field of heart failure management. Areas covered: The literature on decision-analytical models for the economic evaluation of early warning systems for the management of chronic heart failure patients was systematically reviewed...
April 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29210308/using-multi-criteria-decision-analysis-to-appraise-orphan-drugs-a-systematic-review
#19
Carlotta Friedmann, Pierre Levy, Paul Hensel, Mickaël Hiligsmann
Multi-criteria decision analysis (MCDA) could potentially solve current methodological difficulties in the appraisal of orphan drugs. Areas covered: We provide an overview of the existing evidence regarding the use of MCDA in the appraisal of orphan drugs worldwide. Three databases (Pubmed, Embase, Web of Science) were searched for English, French and German literature published between January 2000 and April 2017. Full-text articles were supplemented with conference abstracts. A total of seven articles and six abstracts were identified...
April 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29402128/systematic-review-and-benchmarking-of-quality-adjusted-time-without-symptoms-or-toxicity-q-twist-in-oncology
#20
Caitlyn T Solem, Youngmin Kwon, Ruchit M Shah, Abdalla Aly, Marc F Botteman
The Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) has been used to evaluate the clinical benefits and risks of oncology treatments. However, limited information is available to interpret and contextualize Q-TWiST results. Areas covered: A systematic review of Q-TWiST literature was conducted to provide contextualizing benchmarks for future studies. 51 articles with 81 unique Q-TWiST comparisons were identified. The mean (95% CI) and median absolute Q-TWiST gains for treatment versus control arms were 2...
February 5, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
journal
journal
39911
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"